Radotinib selectively targets and inhibits the BCR-ABL1 fusion protein [6,7,8,9], thereby effectively suppressing the proliferation of leukemic cells in Ph chromosome-positive (Ph+) CML-CP. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.